Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE.

JAMA. 2002 Apr 3;287(13):1690-8.

PMID:
11926893
2.

Pharmacogenetics of warfarin elimination and its clinical implications.

Takahashi H, Echizen H.

Clin Pharmacokinet. 2001;40(8):587-603. Review.

PMID:
11523725
3.

Cytochrome P450 2C9 gene polymorphism and warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis.

Zhang J, Tian L, Huang J, Huang S, Chai T, Shen J.

Cardiovasc Ther. 2017 Feb;35(1):26-32. doi: 10.1111/1755-5922.12230. Review.

PMID:
27661060
4.

Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing.

Redman AR.

Pharmacotherapy. 2001 Feb;21(2):235-42. Review.

PMID:
11213860
5.

Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis.

Yang J, Chen Y, Li X, Wei X, Chen X, Zhang L, Zhang Y, Xu Q, Wang H, Li Y, Lu C, Chen W, Zeng C, Yin T.

Int J Cardiol. 2013 Oct 9;168(4):4234-43. doi: 10.1016/j.ijcard.2013.07.151. Epub 2013 Aug 7. Review.

PMID:
23932037
6.
7.

A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding.

McClain MR, Palomaki GE, Piper M, Haddow JE.

Genet Med. 2008 Feb;10(2):89-98. doi: 10.1097/GIM.0b013e31815bf924. Review.

PMID:
18281915
8.

Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy.

Shaw K, Amstutz U, Kim RB, Lesko LJ, Turgeon J, Michaud V, Hwang S, Ito S, Ross C, Carleton BC; CPNDS Clinical Recommendation Group.

Ther Drug Monit. 2015 Aug;37(4):428-36. doi: 10.1097/FTD.0000000000000192. Review.

9.

Genetic mechanisms for hypersensitivity and resistance to the anticoagulant Warfarin.

Linder MW.

Clin Chim Acta. 2001 Jun;308(1-2):9-15. Review.

PMID:
11412812
10.

Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin.

Kangelaris KN, Bent S, Nussbaum RL, Garcia DA, Tice JA.

J Gen Intern Med. 2009 May;24(5):656-64. doi: 10.1007/s11606-009-0949-1. Epub 2009 Mar 21. Review. Erratum in: J Gen Intern Med. 2009 Dec;24(12):1358.

11.

Optimal loading dose for the initiation of warfarin: a systematic review.

Heneghan C, Tyndel S, Bankhead C, Wan Y, Keeling D, Perera R, Ward A.

BMC Cardiovasc Disord. 2010 Apr 19;10:18. doi: 10.1186/1471-2261-10-18. Review.

12.

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.

Miners JO, Birkett DJ.

Br J Clin Pharmacol. 1998 Jun;45(6):525-38. Review.

13.

Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients.

Palareti G, Cosmi B.

Thromb Haemost. 2009 Aug;102(2):268-78. doi: 10.1160/TH08-11-0730. Review.

PMID:
19652877
14.

[Individualization of drug therapy and pharmacogenetics].

Yamamoto I, Azuma J.

Nihon Rinsho. 1998 Mar;56(3):579-83. Review. Japanese.

PMID:
9549339
15.

Influence of APOE Gene Polymorphism on Interindividual and Interethnic Warfarin Dosage Requirement: A Systematic Review and Meta-Analysis.

Yu WY, Sun X, Wadelius M, Huang L, Peng C, Ma WL, Yang GP.

Cardiovasc Ther. 2016 Oct;34(5):297-307. doi: 10.1111/1755-5922.12186. Review.

PMID:
27062534
16.

Pharmacogenetics and oral antithrombotic drugs.

Baker WL, Johnson SG.

Curr Opin Pharmacol. 2016 Apr;27:38-42. doi: 10.1016/j.coph.2016.01.008. Epub 2016 Feb 15. Review.

PMID:
26878737
17.

Anticoagulation-related nephropathy.

Wheeler DS, Giugliano RP, Rangaswami J.

J Thromb Haemost. 2016 Mar;14(3):461-7. doi: 10.1111/jth.13229. Epub 2016 Feb 15. Review.

PMID:
26670286
18.

Genotype-guided dosing of warfarin through modeling and simulation.

Deng J, Vozmediano V, Rodriguez M, Cavallari LH, Schmidt S.

Eur J Pharm Sci. 2017 May 11. pii: S0928-0987(17)30245-2. doi: 10.1016/j.ejps.2017.05.017. [Epub ahead of print] Review.

PMID:
28502675
19.

Preventing Medication Errors in Ambulatory Care: The Importance of Establishing Regimen Concordance.

Schillinger D, Machtinger E, Wang F, Rodriguez M, Bindman A.

In: Henriksen K, Battles JB, Marks ES, Lewin DI, editors. Advances in Patient Safety: From Research to Implementation (Volume 1: Research Findings). Rockville (MD): Agency for Healthcare Research and Quality (US); 2005 Feb.

20.

Influence of the CYP4F2 polymorphism on the risk of hemorrhagic complications in coumarin-treated patients.

Chen P, Sun YQ, Yang GP, Li R, Pan J, Zhou YS.

Saudi Med J. 2016 Apr;37(4):361-8. doi: 10.15537/smj.2016.4.14036. Review.

Supplemental Content

Support Center